Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution (Tigris)
A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety, Efficacy, and Dose-response of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Chris Hafner
- Phone Number: 18184421564
- Email: chris@spyglasspharma.com
Study Locations
-
-
Arizona
-
Glendale, Arizona, United States, 85306
- Arizona Advanced Eye Research Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension
- Planned removal of cataract
- Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit and agree to the use of contraception
Exclusion Criteria:
- Uncontrolled systemic disease
- History of incisional/refractive corneal surgery
- Any glaucoma diagnosis other than OHT, open-angle, pseudoexfoliation, or pigmentary glaucoma
- History of incisional glaucoma surgery or intraocular injections
- Other ocular diseases, pathology, or conditions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Bimatoprost Implant System (High Dose) / IOL Combination
|
Bimatoprost Implant System (High Dose) used in combination with the SpyGlass IOL
SpyGlass Intraocular Lens
|
|
Experimental: Bimatoprost Implant System (Low Dose) / IOL Combination
|
SpyGlass Intraocular Lens
Bimatoprost Implant System (Low Dose) used in combination with the SpyGlass IOL
|
|
Active Comparator: Timolol Maleate Ophthalmic Solution 0.5%
|
Timolol Maleate Ophthalmic Solution 0.5% BID
Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean IOP Reduction from Baseline (mmHg)
Time Frame: Weeks 2 and 6, and Month 3
|
Time matched mean IOP reduction from Baseline (mmHg) in the study eyes at all the individual IOP timepoints
|
Weeks 2 and 6, and Month 3
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean IOP
Time Frame: Weeks 2 and 6 and Months 3, 6, 12, 18, 24, 27, 30, 33, and 36
|
Time matched mean IOP (mmHg) at Weeks 2 and 6 and Months 3, 6, 12, 18, 24, 27, 30, 33, and 36
|
Weeks 2 and 6 and Months 3, 6, 12, 18, 24, 27, 30, 33, and 36
|
|
Mean IOP Change from Baseline
Time Frame: Months 6, 12, 18, 24, 27, 30, 33, and 36
|
Time matched mean IOP change from Baseline (mmHg) at Months 6, 12, 18, 24, 27, 30, 33, and 36
|
Months 6, 12, 18, 24, 27, 30, 33, and 36
|
|
Time to postoperative introduction of IOP-lowering medications
Time Frame: Total Study Period of 36 Months
|
Time (Days) to postoperative introduction of IOP-lowering medications (IOP-lowering medications other than the study treatments)
|
Total Study Period of 36 Months
|
|
Number of IOP-lowering medications introduced postoperatively
Time Frame: Total Study Period of 36 Months
|
Number of IOP-lowering medications introduced postoperatively (N) at Weeks 2 and 6, and Months 3, 6, 12, 18, 24, 27, 30, 33, and 36
|
Total Study Period of 36 Months
|
|
Proportion of eyes achieving BCDVA 20/40 or better
Time Frame: Months 3, 6, and 12
|
Snellen Equivalent
|
Months 3, 6, and 12
|
|
Manifest refraction spherical equivalent
Time Frame: Month 3
|
Manifest refraction spherical equivalent (MRSE)
|
Month 3
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number and Rates of Adverse Events
Time Frame: Total Study Period of 36 Months
|
Total Study Period of 36 Months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Chris Hafner, SpyGlass Pharma, Inc.
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Lens Diseases
- Cataract
- Ocular Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Agents
- Anti-Arrhythmia Agents
- Adrenergic Agents
- Pharmaceutical Solutions
- Antihypertensive Agents
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Bimatoprost
- Ophthalmic Solutions
- Timolol
Other Study ID Numbers
Other Study ID Numbers
- SGP-003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.